India has marked a significant advancement in public healthcare by validating its first indigenous Human Papillomavirus (HPV) test for cervical cancer screening. The validation has been carried out by leading medical and research institutions including the All India Institute of Medical Sciences (AIIMS) and the Indian Council of Medical Research (ICMR), in collaboration with global health experts from the World Health Organization’s International Agency for Research on Cancer (IARC).
This development is a major step toward making cervical cancer screening more affordable, accessible, and scalable across India, especially in rural and underserved regions where diagnostic facilities remain limited.
The newly validated HPV test has been designed and developed within India under collaborative research initiatives. The test is capable of detecting high-risk HPV strains responsible for cervical cancer, which account for the majority of cervical cancer cases globally.
Earlier screening methods in India relied on less accurate approaches like Visual Inspection with Acetic Acid (VIA), which often produced false positives and limited reliability. The indigenous HPV test aims to overcome these limitations by offering high accuracy and international-standard validation.
The validation process involved multiple premier institutions including AIIMS Delhi, ICMR research centers, and global collaboration support from WHO-IARC. The testing and evaluation were conducted across multiple laboratories to ensure reliability, accuracy, and reproducibility.
The study confirmed that at least one indigenous test (Truenat HR-HPV-Plus) met global validation standards, marking a breakthrough for India’s diagnostic capabilities.
Cervical cancer is one of the leading cancers affecting women in India, contributing to a large number of preventable deaths each year. The introduction of an affordable HPV test can significantly improve early detection rates and reduce mortality.
This innovation is expected to strengthen India’s national cervical cancer elimination strategy and support large-scale screening programs under public health missions.
This development is crucial because it enhances India’s capacity for early detection of cervical cancer, which is one of the most preventable yet deadly cancers among women. Early screening through HPV testing can drastically reduce mortality rates.
The indigenous HPV test reduces dependency on expensive imported diagnostic kits. This makes it possible for government health programs to implement mass screening at lower costs, especially in rural and economically weaker regions.
The innovation aligns with India’s broader public health goals, including cancer prevention, women’s health improvement, and universal healthcare access. It also supports WHO’s global cervical cancer elimination targets.
The validation of an indigenous diagnostic tool strengthens India’s position in medical research and biotechnology innovation, contributing to the vision of Atmanirbhar Bharat in healthcare.
Traditionally, cervical cancer screening in India relied on methods such as Pap smears and VIA tests, which were either resource-intensive or less accurate. These limitations resulted in delayed diagnosis in many cases.
Over the years, AIIMS and ICMR have played a central role in developing and testing diagnostic tools for infectious and non-communicable diseases. Their collaboration with international bodies like WHO-IARC has helped bring global standards to Indian healthcare research.
The World Health Organization has recommended HPV-based screening as the most effective method for cervical cancer prevention. Many countries have already adopted HPV testing as part of national screening programs, and India is now aligning with this global standard.
The indigenous HPV test is a major breakthrough in cervical cancer screening as it enables early detection of high-risk HPV strains, helping reduce cervical cancer cases and deaths in India.
The test was validated by the All India Institute of Medical Sciences (AIIMS) and the Indian Council of Medical Research (ICMR) in collaboration with international experts from WHO-IARC.
The HPV test primarily detects Human Papillomavirus (HPV) infections, especially high-risk strains responsible for causing cervical cancer in women.
HPV testing helps in early identification of infection before cancer develops, allowing timely treatment and significantly reducing mortality rates.
It will make cervical cancer screening more affordable, scalable, and accessible, especially in rural and low-resource healthcare settings.
The World Health Organization (WHO) recommends HPV-based screening as the most effective method for cervical cancer prevention.
Yes, cervical cancer is largely preventable through HPV vaccination, regular screening, and early medical intervention.
KHAAN QUEST 2026 Exercise: Indian Army contingent of 40 personnel from the JAT Regiment leaves…
QS World University Rankings 2027 India update shows India ranking 5th globally with 52 universities…
World Sickle Cell Day 2026 theme highlights closing the survival gap in sickle cell care.…
China Brahmaputra Dam project 2026 on Yarlung Tsangpo River is the world’s largest hydropower initiative…
RBI cancels bank licence of Shree Mahalaxmi Co-operative Credit Bank due to weak financial health;…
Lab-grown diamond manufacturing in Odisha gains momentum as the state approves ₹76,612 crore investment projects…